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Abstract 
Background: Although site-directed genetic engineering has greatly improved in 
recent years, particularly with the implementation of CRISPR-Cas9, the ability to deliver 
these molecular constructs to a wide variety of cell types without adverse reaction 
is still a challenge. One non-viral transfection method designed to address this chal-
lenge is a MEMS based biotechnology described previously as lance array nanoinjec-
tion (LAN). LAN delivery of molecular loads is based upon the combinational use of 
electrical manipulation of loads of interest and physical penetration of target cell 
membranes. This work explores an original procedural element to nanoinjection by 
investigating the effects of the speed of injection and also the ability to serially inject 
the same sample.
Results: Initial LAN experimentation demonstrated that injecting at speeds of 
0.08 mm/s resulted in 99.3 % of cultured HeLa 229 cells remaining adherent to the 
glass slide substrate used to stage the injection process. These results were then 
utilized to examine whether or not target cells could be injected multiple times (1, 2, 
and 3 times) since the injection process was not pulling the cells off of the glass slide. 
Using two different current control settings (1.5 and 3.0 mA) and two different cell 
types (HeLa 229 cells and primary neonatal fibroblasts [BJ(ATCC® CRL-2522™)], treat-
ment samples were injected with propidium iodide (PI), a cell membrane impermeable 
nucleic acid dye, to assess the degree of molecular load delivery. Results from the serial 
injection work indicate that HeLa cells treated with 3.0 mA and injected twice (×2) had 
the greatest mean PI uptake of 60.47 % and that neonatal fibroblasts treated with the 
same protocol reached mean PI uptake rates of 20.97 %.
Conclusions: Both experimental findings are particularly useful because it shows that 
greater molecular modification rates can be achieved by multiple, serial injections via a 
slower injection process.
Keywords: Lance array nanoinjection, Speed of injection, Serial injection,  
Injection-dose response
Open Access
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and 
indicate if changes were made.
RESEARCH






and Molecular Biology, 
Brigham Young University, 
Provo, UT 84602, USA
Full list of author information 
is available at the end of the 
article
Page 2 of 18Sessions et al. SpringerPlus  (2016) 5:1093 
Background
Gene therapy and gene medicine approaches to correcting disease represent a major 
paradigm shift in how clinicians are able to help patients, moving from a framework of 
reactionary treatment of disease manifestations to fundamental, proactive prevention 
of genetic alterations causing the disease (Byrne et  al. 2012; Griesenbach et  al. 2015; 
Shimamura et  al. 2013). While still in a relatively early stage of development, medical 
approaches designed to engineer genetic outcomes have had promising results in terms 
of both monogenic (Bainbridge et al. 2008; Hauswirth et al. 2008; Jacobson et al. 2012; 
Maguire et  al. 2008; Patel et  al. 2014; Sahel and Roska 2013; Yla-Herttuala 2012) and 
polygenic (Jessup et  al. 2011; Kochenderfer and Rosenberg 2013; Kranias and Hajjar 
2012; Sikkel et al. 2014; Simonato et al. 2013; Zsebo et al. 2014) disease corrections.
Unfortunately, the actual method for transmission of the genetic loads to target cells 
remains a challenge (Doherty and McMahon 2009; Khalil et al. 2006; Lukacs et al. 2000; 
Mellott et al. 2013). Many biotechnologies have been created to help address this issue 
(with mixed results) (Choi et  al. 2010; Jen et  al. 2004; Lin and Huang 2001; Lin et  al. 
2001; Wiethoff and Middaugh 2003). The primary goal of all of these methods is to site-
direct genetic loads into cells without harming the host systemically or the target cell 
locally (Mellott et al. 2013). Key features frequently noted as critical design requirements 
for these biotechnologies include:
  • High transfection efficiency
  • Effective in a wide range of cell types
  • Flexible pay load capacity
  • No immunologic response
  • No insertional mutagenesis
One non-viral transfection biotechnology, known as lance array nanoinjection (LAN), 
has been created with these design requirements in mind. LAN works by using a com-
bination of physical penetration of target cell membranes and electrical delivery of 
molecular loads using a microfabricated silicon etched array of lances (Lindstrom et al. 
2014; Teichert et al. 2013). Figure 1 shows an SEM image of a lance array which contains 
10  μm length lances spaced 10  μm from center to center in a grid pattern, ultimately 
forming 4 million lances on a 2 by 2 cm chip.
Procedurally, nanoinjection works in a series of four major steps which include: stag-
ing the lance in the solution containing the desired molecular load, electrical attraction 
of the molecular load onto the lance, physical penetration of the cell membrane of tar-
get cells and electrical repulsion of the molecular load into the cytoplasmic space, and 
finally removal of the lance (Aten et  al. 2011, 2012; Wilson et  al. 2013) (see Fig.  2 for 
illustration of LAN process).
There are several attractive features of LAN relative to other transfection methods. 
First, it does not rely on delivery agents that can cross-react with the immune system 
[such is the case with several viruses (Follenzi et al. 2007; Matrai et al. 2010; Mellott et al. 
2013; Ritter et al. 2002; VandenDriessche et al. 2002)], nor does it create cytotoxic effects 
in target cells [such is the case with many chemical based methods (Mellott et al. 2013; 
Wiethoff and Middaugh 2003)]. Second, because the lances are 1–2.5 μm in diameter, 
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the resulting pores created during the injection event are relatively large, making it pos-
sible for large molecules to transiently pass into the cell. Even though the pores are rela-
tively large, the trauma induced during the process is relatively minimal, as evidenced 
by high cell viability rates (78–91 %) previously noted (Lindstrom et al. 2014). This latter 
feature of cell viability is an issue in some instrumentation based transfection methods, 
such as electroporation (Barsoum 1995) and microinjection (Aten et al. 2012).
Fig. 1 SEM image of two rows of lances contained on the lance array silicon chip. Lances measure 10 μm in 
length, 1–2.5 μm in diameter, and spaced 10 μm from center to center
Fig. 2 Lance array nanoinjection stepwise process. 1 Staging the lance array in the solution containing the 
desired molecular load. 2 Electrical attraction of the molecular load onto the lances. 3 Physically penetrating 
the cell membrane of target cells and electrical repulsion of the molecular load into the cytoplasmic space.  
4 Removal of the lance array, leaving the molecular load in the intracellular space of target cells
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Despite these attractive features of LAN, one short-coming that LAN as well as all 
non-viral transfection technologies encounter is that transfection rates are lower than 
what can be achieved with viral modalities (Mellott et  al. 2013). This work seeks to 
directly address this challenge related to efficient molecular delivery by considering two 
intertwined procedural variables unique to LAN which include: the speed of injection 
and serial injection of the same sample. In prior testing, it has been noted that following 
a single injection event, many cells do not stay adherent to the glass slide used for stag-
ing the injection process. The purpose of investigating the effect of speed of injection 
is to determine the extent that cell removal can be minimized such that serial injection 
protocols can be investigated.
Indeed, it is shown in this work that by slowing the speed of the injection process that 
target cells are able to remain adherent to the glass slide using for staging the injection. 
Because the cells remain post-injection, it is possible to inject multiple times and thereby 
increase the amount of molecular load delivered to the cell.
To help establish the robustness of this procedural investigation, as part of the serial 
injection testing, two different cell types, immortalized HeLa culture and primary neo-
natal fibroblast cells, were used to determine how the different cell types respond. To 
demonstrate molecular load delivery, propidium iodide (PI), a dye typically imperme-
able to the cell membrane, was used in conjunction with flow cytometry to quantify the 
injection-dose response.
Because the speed of injection experimentation led to serial injection experimenta-
tion, the following will be compartmentalized to consider the speed of injection work 
first, followed immediately by the serial injection work.
Methods: General
This work consists of two major experiments—the speed of injection and serial injection 
experiments. The speed of injection work, which is presented first, is a precursor experi-
ment that led to further exploration that makes up the serial injection experiment. Both 
used common experimental elements which are detailed in this general methods sec-
tion. For experimental elements unique to the specific experiment, separate descriptions 
are provided.
Lance array fabrication
Reference (Teichert et al. 2013) provides a complete description of the microfabrication 
process used for creating the silicon lance array and is presented here simply for conven-
ience. The lance array microfabrication process consisted of using positive photoresist 
(AZ330F) to pattern a grid of circles that became pillar-like structures following deep 
reactive ion etching (DRIE). These pillars were then treated with a sulfur hexafluoride 
(SF6) isotropic plasma etch, which serves to form a pointed tip on the pillars, resulting in 
lances (see Fig. 1).
Injection set‑up
Figure  3 shows a schematic, cross-sectional view of the injection device and contains 
eight major components which include: stepper motor, threaded rod, coiled spring, 
orthoplanar spring, electrical connections, silicon lance array, glass slide for the cell 
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culture, and cell culture platform. The stepper motor and electrical connections receive 
input signals from the electrical control box (see Fig. 4). During the injection process, 
the stepper motor causes the threaded rod to vertically displace the coiled and orthopla-
nar springs. The lance array is attached to the inferior surface of the orthoplanar spring 
and interacts with the cell culture contained on the glass slide according the process out-
lined in Fig. 2. The cell culture platform serves to facilitate alignment with the orthop-
lanar spring and also helps fix the glass slide, preventing it from adhering to the silicon 
lance array.
Electrical control box
The electrical control box, which provides electrical input to the injection device, oper-
ates by receiving three inputs from three separate power supplies (2400 SourceMeter, 
Keithley) (see Fig. 4). Figure 5 is a full electrical schematic of the electrical control box 
where it illustrates electrical inputs from the power supplies running through two relays 
arranged in series. The first relay was used to allow either Input 1 or 2 to pass, while 
Fig. 3 Cross-sectional schematic of injection device. Components include (top–bottom): stepper motor, 
threaded rod, coiled and orthoplanar springs, electrical connections, silicon lance array, glass slide for cell 
culture, and cell culture platform
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the second relay was used to allow the input from the previous relay or Input 3 to pass. 
This allowed one input at a time to pass using two digital pins (one to control each relay, 
using 5 V or GND).
Fig. 5 Electrical schematic for the current control box. An Arduino was used to control two relays and a step-
per motor driver for the injection process. Five LEDs are used as indicators for power, output, and which input 
being passed through the box
Fig. 4 Experimental set-up showing the electrical control box receiving three separate input signals coming 
from three power supplies (not shown) and outputting appropriately timed output signals to the injection 
device mounted above the prepared six-well plate. Cell culture platforms with the prepared cell cultures are 
seen as white and red circular components resting in the wells of the six-well plate
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The output signals from the electrical control box used for the serial injection testing 
can be described as the following: Output 1, current controlled of either 1.5 or 3.0 mA 
for 20 s; Output 2, 10 intermittent pulsing events between 0 and +7 V for 20 ms (2 ms 
period); Output 3, 5 s interval of +1.5 V. In addition to these actions, the electrical con-
trol box also operates the stepper motor attached to the superior end of the injection 
device. It should be noted, Outputs 2 and 3 occur when the lances are inserted into the 
cells.
Methods: Speed of injection experimentation
Stepper motors
Two separate stepper motors [28BYJ-48-5V, Rohs; TSFNA25-150-17-023-LW4, Ana-
heim Automation (AA)] were used to for the speed of injection testing in order to 
achieve the speeds needed and still ensure that the stepper motors would not skip steps 
by being driven too quickly. Five different speeds were used for this experiment, which 
include 0.08, 0.16, 0.60, 1.80, 3.00 mm/s. For the slower speeds of 0.08 and 0.16 mm/s, 
the Rohs stepper motor was used and for 0.60, 1.80, and 3.00 mm/s speeds, the AA step-
per motor was used. The injection device was the same for all sets of injection tests, with 
the exception of the stepper motor being changed to match speed conditions.
Cell culture preparation
For all experiments, untreated glass coverslip slides were used as the substrate for seed-
ing cells. HeLa 229 cells were plated on glass slides within six-well plates (Sarstedt) and 
incubated at 37 °C and 5 % carbon dioxide. Culture media contained Dulbeccos Modi-
fied Eagles Medium (DMEM, Gibco) with 10 % Fetal Bovine Serum (FBS, Denville Sci-
entific) and streptomycin/penicillin (Gibco). Cell cultures were allowed to incubate for 
24 h following the plating process to ensure adequate adherence to the glass slide. Fol-
lowing the 24 h, a mono-layer of HeLa cells, which were approximately 70 % confluent, 
had their growth media removed and were re-supplied with 2 mL of phosphate buffered 
solution (PBS, Gibco) in final preparation for injection.
Treatment protocols
The following describes the various sample types used in the speed of injection testing:
Non-Treatment Control (NTC): Received no lancing.
Treatment Protocol for Different Speeds: Samples were lanced a single time and received 
no applied voltage during the injection process. Five different injection speeds were 
applied during the injection event and include: 0.08, 0.16, 0.60, 1.80, 3.00 mm/s.
As a convention, specific treatment sample types will be designated by the speed of 
injection. For example, HeLa/0.08 refers to a treatment sample that was lanced a single 
time at 0.08 mm/s.
Post‑treatment analysis
After the injections were completed, all samples were given 0.5  mL of 5× trypsin 
(Gibco) and incubated 5  min at 37  °C to facilitate removal of the cells from the glass 
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slides. After the 5 min, samples were treated with 1.5 mL of DMEM/FBS media to deac-
tivate the trypsin and then centrifuged at 2000  rpm for 10  min. The supernatant was 
then removed, 0.25 mL of PBS was added to each sample, and each sample was then vor-
texed to prepare them for hemocytometry. Quantification of the number of cells were 
performed according to standard hemocytometry methods using trypan blue (Caprette 
2012).
Statistical analysis
After cell counts were obtained using hemocytometry, data for treatment samples were 
normalized relative to the Non-Treatment Controls according to the following formula.
This normalized data was then statistically analyzed in JMP (SAS), using initially an 
ANOVA test to screen for statistically significant relationships (F-ratio: 16.5426) fol-
lowed by individual student t-tests (α = 0.05).
Results and discussion: Speed of injection experimentation
Figure 6 shows a set of box plot results for the data generated for the five different injec-
tion speeds. The left-most two box plots were obtained by using the slower stepper 
motor (Rohs), while the other three box plots were obtained from the slightly faster step-
per motor (AA). It can be seen that statistically significant relationships exist in all cases 
between the slower and faster stepper motors (<0.0001) (see Table 1).
Table  2 provides a summary of the results showing that for both the 0.08 and 
0.16 mm/s speeds, that the mean normalized cell count is more than double the highest 
normalized mean obtained with the faster stepper motor.
Suggested in these results is that the cultured cells are able to adhere better to the glass 
surface used for staging the injection when using injection speeds of 0.08–0.16 mm/s. 
(1)
Cell Count in Treatment Sample
Cell Count inNon-Treated Control (NTC)
Fig. 6 Injection speed box plot. The two left-most box plots were the result of the slower stepper motor (Rohs) 
whereas the three right-most box plots were the result of the faster stepper motor (AA). Statistically significant 
relationships are noted with an asterisk
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These findings are consistent with atomic force microscopy (AFM)-based single-cell 
force spectroscopy (SCFS) studies (Benoit et  al. 2000; Evans and Calderwood 2007; 
Florin et al. 1994; Helenius et al. 2008; Hong et al. 2012; Lehenkari and Horton 1999; 
Zhang et al. 2002). Friedrichs et al. (2013) demonstrated with a single cell adhered to an 
AFM probe by cell adhesion molecules (CAMs), that when placed in contact with a sub-
strate surface, the speed with which the AFM probe was removed was directly related 
to the viscous forces created between the substrate surface and the cell. If sufficiently 
strong viscous forces were generated by removing the AFM probe (with the attached 
cell) fast enough, the cell would experience a series of five major events which include:
1. Shrinking of the surface area contact between the cell and substrate surface.
2. Cell body removal from the substrate with only membrane nanotubes linking the cell 
and substrate.
3. Stressing of the CAM linkages between the cell and AFM probe—reaching a non-lin-
ear maximum level as cytoskeletal structures are strained in the direction of motion.
4. Peripheral rupture of the CAM structures leading to a rapid decrease in adhesion 
force between the cell and the AFM probe.
5. Cell removal from the AFM probe as the viscous effects from the substrate-cell inter-
face overcome the cellular adhesion to the AFM probe.
Returning to the context of LAN, it is suggested that for the majority of cells present 
on the glass slides that experience injection speeds of ≤0.16  mm/s, that the viscous 
forces created by the removal of the silicon lance array does not exceed the strength with 
which the cells are adhered to the glass slide. For treatment samples experiencing greater 
speeds of lance array removal, it appears that fewer cells are able to withstand these 
removal forces and are pulled away from the glass.
Table 1 P values for speed of injection experiment
Comparison P value Comparison P value
HeLa/0.08 versus HeLa/0.16 0.6466 HeLa/0.16 versus HeLa/1.80 <0.0001
HeLa/0.08 versus HeLa/0.60 <0.0001 HeLa/0.16 versus HeLa/3.00 <0.0001
HeLa/0.08 versus HeLa/1.80 <0.0001 HeLa/0.60 versus HeLa/1.80 0.7180
HeLa/0.08 versus HeLa/3.00 <0.0001 HeLa/0.60 versus HeLa/3.00 0.4362
HeLa/0.16 versus HeLa/0.60 <0.0001 HeLa/1.80 versus HeLa/3.00 0.2566
Table 2 Statistical summary for injection speed experiment
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Methods: Serial injection experimentation
Using the fact that slowing the injection process results in an increase in cell number 
remaining on the glass slide substrate used for staging the injection process, it was 
proposed to investigate whether or not target cells could be injected multiple times 
and exhibit an increase in molecular load delivery. Furthermore, it was also proposed 
to determine whether a difference exists in molecular delivery when using different 
cell types. To explore this latter item, two cell types were selected which include HeLa 
229 cells (commonly used in basic research) and primary, human neonatal fibroblasts 
[BJ(ATCC® CRL-2522™)] (used in wound healing applications).
For convenience, the injection speed of 0.16  mm/s was used for the serial injection 
testing because it was twice as fast as the 0.08 mm/s speed setting and still had a high 
mean number of cells still adherent to the glass slide following injection (i.e. 94.6 %).
Cell culture preparation
For both cell types, test preparation began with seeding glass slides contained within six-
well plates with 2 mL of a growth media, which consisted of: Dulbeccos Modified Eagles 
Medium (DMEM, Gibco), 10 % Fetal Bovine Serum (FBS, Denville Scientific), and strep-
tomycin/penicillin (Gibco). Cells were incubated overnight prior to injection at standard 
conditions of 37 °C and 5 % carbon dioxide.
Following this process, glass slides were transferred to new six-well plates and snapped 
into 3D printed cell culture platforms (used to help align the injection device). Cells, 
now staged for the injection process, were given 2 mL of phosphate buffered solution 
(PBS, Gibco) per well. At this point, both cell types had formed a mono-layer of approxi-
mately 70 % confluency.
Propidium iodide
Propidium iodide (Sigma-Aldrich) was used as a molecular marker in this experiment 
because it is typically impermeable to the cell membrane. Because the lances used in 
LAN penetrate target cells and then deliver PI to the intracellular space of these tar-
get cells, it is an indicator of successful delivery. Once in the cell, PI can intercalate will 
nucleic acids, which results in fluorescent activity 20–30 times greater than normal, 
thereby providing a detectable means of transfection rates during flow cytometry.
Treatment protocols
Treatment samples were generated using the following protocols for both HeLa and 
Fibroblast cells which include:
Non-Treatment Control (NTC): Received no lancing, no applied voltage, and no PI.
Background Control for PI (BC): Received no lancing, no applied voltage. Received 
0.02 mg/mL PI.
Treatment Protocol 1.5 or 3.0 mA, injected 1, 2, or 3 times: Lanced, receive 0.02 mg/
mL PI, and received current control which consisted of: 20 s application of either 1.5 
or 3.0 mA, followed by 10 intermittent pulsing events between 0 and +7 V for 20 ms 
(2 ms period), followed by 5 s of a +1.5 DC voltage.
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The parameters for treatments were selected based on data from previous work (Lind-
strom et  al. 2014) with the exception of changing the initial voltage control setting to 
be a current control setting. This modification allows the molecular load of interest to 
be electrically attracted to the lance array in greater quantities because there is current 
flowing continuously in the solution as opposed to the voltage control setting that sees 
an exponential decay in current flow in the solution. Those treatment samples that were 
injected more than once were incubated without changing media for 1 h before the sam-
ple was injected again. This refractory period has been shown in previous testing to pre-
vent excessive stress to target cells.
As a convention, specific treatment sample types will be designated by cell type, cur-
rent control setting used during injection, and the number of times the sample was 
injected. For instance, Fibro 1.5 mA, ×2 refers to a fibroblast treatment sample that was 
injected with 1.5 mA (used for Input 1), two times.
Post testing flow cytometry preparation
Following injections, all samples were incubated for 2  h prior to being treated with 
0.5 mL of 5× Trypsin (Gibco) and incubated for 5 min for removal of cells from the glass 
slide. Following treatment with trypsin, samples were given 1.5  mL of DMEM/FBS to 
deactivate the trypsin. After transferring individual samples to FACS tubes, the samples 
were centrifuged for 10 min at 2000  rpm. Final preparation for flow cytometry of the 
samples include decanting supernatants and re-suspending cell pellets in 0.5 mL of PBS.
Flow cytometry
Quantification of samples was performed using flow cytometry (Attune Acoustic Focus-
ing Flow Cytometer, Life Technologies). Approximately 20,000 events were captured and 
characterized for each sample. Data extraction was performed using Attune Cytomet-
ric 2.1 software (Applied Biosystems, Life Technologies) by facilitating visualization of 
events, gating of appropriate cell populations, and developing primary level data usable 
for JMP (SAS) statistical analysis.
Statistical analysis
Primary level data generated from post-flow analysis in Attune Cytometric software was 
evaluated in a two-part process. First, the percentage of living, PI positive cells in each 
sample were calculated according to the following formula:
Second, data was then screened in JMP for statistical significance using ANOVA test 
(F-ratio for HeLa study: 21.0098; F-ratio for Fibroblast study: 49.1873) followed by indi-
vidual student t-tests (α = 0.05).
Results and discussion: Serial injection experimentation
Figure 7 shows box plot results of the HeLa cell serial injection experiment. Three find-
ings can be seen in these plots and quantitatively represented in Tables 3 and 4. First, the 
samples receiving 3.0 mA during Input 1 had a higher mean number of modified cells 
(2)
Number of Living PI Positive Cells in Sample
Number of Living Cells in Sample
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than samples receiving 1.5 mA. The relative maximum for the 3.0 mA samples reached 
a mean value of 60.47 %, which is nearly four times greater than the relative maximum 
achieved for the 1.5 mA group. Second, within groups receiving the same current control 
during Input 1 of the injection process, samples that were injected twice had a higher 
mean number of modified cells than those samples injected one or three times. Third, 
within the current control groups, both groups receiving three injections had mean val-
ues for PI uptake that were intermediate levels for the current control group.
Fig. 7 Mean percentage of living/propidium iodide positive HeLa cells for all sample types. Because of the 
number of statistical relationships that were derived, statistically significant relationships are not noted on the 
box plot figure. For statistical significant relationships, reference Table 3
Table 3 P value for HeLa serial injection experiment
Comparison P value Comparison P value
NTC versus BC 0.5813 1.5 mA, ×1 versus 1.5 mA, ×3 0.3578
NTC versus 1.5 mA, ×1 0.2629 1.5 mA, ×1 versus 3.0 mA, ×1 0.0009
NTC versus 1.5 mA, ×2 0.0114 1.5 mA, ×1 versus 3.0 mA, ×2 <0.0001
NTC versus 1.5 mA, ×3 0.0346 1.5 mA, ×1 versus 3.0 mA, ×3 <0.0001
NTC versus 3.0 mA, ×1 <0.0001 1.5 mA, ×2 versus 1.5 mA, ×3 0.6946
NTC versus 3.0 mA, ×2 <0.0001 1.5 mA, ×2 versus 3.0 mA, ×1 0.0381
NTC versus 3.0 mA, ×3 <0.0001 1.5 mA, ×2 versus 3.0 mA, ×2 <0.0001
BC versus 1.5 mA, ×1 0.5299 1.5 mA, ×2 versus 3.0 mA, ×3 <0.0001
BC versus 1.5 mA, ×2 0.0402 1.5 mA, ×3 versus 3.0 mA, ×1 0.0141
BC versus 1.5 mA, ×3 0.1032 1.5 mA, ×3 versus 3.0 mA, ×2 <0.0001
BC versus 3.0 mA, ×1 <0.0001 1.5 mA, ×3 versus 3.0 mA, ×3 <0.0001
BC versus 3.0 mA, ×2 <0.0001 3.0 mA, ×1 versus 3.0 mA, ×2 <0.0001
BC versus 3.0 mA, ×3 <0.0001 3.0 mA, ×1 versus 3.0 mA, ×3 0.0274
1.5 mA, ×1 versus 1.5 mA, ×2 0.1903 3.0 mA, ×2 versus 3.0 mA, ×3 0.0574
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Figure 8 shows the box plot results for the serial injection of primary, fibroblasts using 
the two different current control settings. Two main features are observed in the results. 
First, the Fibro 3.0 mA, ×2 sample group had the highest mean percent of modified cells 
for all samples (i.e. 20.97 %), being more than three times greater than the best mean 
percent in the 1.5  mA group. Second, similar to the behavior seen in the HeLa sam-
ples for serial injection, the fibroblasts treated with 3.0 mA also had a relative maximum 
mean value for the two times injected group.
Tables 5 and 6 provide both statistically significant relationship and summaries for the 
experiment. Of note, the fibroblasts exhibit lower mean values for the PI delivery than 
analogous HeLa samples. Also of note, the HeLa samples that were treated with 3.0 mA 
had a much larger variability in the grouping of data points when compared to the fibro-
blast 3.0 mA treatment groups.
Table 4 Statistical summary for HeLa cell serial injection experiment
Sample type Sample size (n) Mean (%)
HeLa, NTC 24 0.1996
HeLa, BC 24 3.3325
HeLa 1.5 mA, ×1 16 7.3231
HeLa 1.5 mA, ×2 16 16.4594
HeLa 1.5 mA, ×3 16 13.7281
HeLa 3.0 mA, ×1 16 30.9944
HeLa 3.0 mA, ×2 15 60.4720
HeLa 3.0 mA, ×3 15 46.7300
Fig. 8 Mean percentage of living/propidium iodide positive fibroblast cells for all sample types. Because of 
the number of statistical relationships that were derived, statistically significant relationships are not noted on 
the box plot figure. For statistical significant relationships, reference Table 3
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Key elements shown in the results of both HeLa and fibroblast cells is that the cells 
respond to the series of injections by having an increase in PI introduction, with the 
exception of the samples injected 3 times. Two possibilities to explain the decrease in PI 
observed in three times injected samples are related to physiologic responses to LAN. 
One possibility is that the 1 h rest period given to the cells following injection is not long 
enough for cellular structures to recover from the injection event. Even though LAN has 
been shown to be mild in terms of cell viability after a single injection event (Lindstrom 
et al. 2014), it is possible that after three injections, that a longer rest period is required 
in order to reduce cellular stress and increase cell survival rates. A second possibility 
is related to the effects on the cellular adhesion to the glass slide following injection. 
Perhaps even though cells are able to maintain adhesion to the glass slide at high rates 
(as shown in the first portion of this work), that residual strain collects in the CAM 
structures and after three times of injection, the CAM can no longer adhere to the glass, 
resulting in a decreased observed number of PI in the sample. Suggested here is fur-
ther investigation into what effects the rest period duration has on the ability of cultured 
cells to withstand multiple injection events. Treatment of the substrate for different cell 
adhesion was not explored since all of the experiments presented here utilized untreated 
Table 5 P values for fibroblast serial injection experiment
Comparison P value Comparison P value
NTC versus BC <0.0001 1.5 mA, ×1 versus 1.5 mA, ×3 0.1745
NTC versus 1.5 mA, ×1 <0.0001 1.5 mA, ×1 versus 3.0 mA, ×1 <0.0001
NTC versus 1.5 mA, ×2 0.0028 1.5 mA, ×1 versus 3.0 mA, ×2 <0.0001
NTC versus 1.5 mA, ×3 0.0095 1.5 mA, ×1 versus 3.0 mA, ×3 <0.0001
NTC versus 3.0 mA, ×1 <0.0001 1.5 mA, ×2 versus 1.5 mA, ×3 0.6654
NTC versus 3.0 mA, ×2 <0.0001 1.5 mA, ×2 versus 3.0 mA, ×1 <0.0001
NTC versus 3.0 mA, ×3 <0.0001 1.5 mA, ×2 versus 3.0 mA, ×2 <0.0001
BC versus 1.5 mA, ×1 0.6775 1.5 mA, ×2 versus 3.0 mA, ×3 <0.0001
BC versus 1.5 mA, ×2 0.5598 1.5 mA, ×3 versus 3.0 mA, ×1 <0.0001
BC versus 1.5 mA, ×3 0.2826 1.5 mA, ×3 versus 3.0 mA, ×2 <0.0001
BC versus 3.0 mA, ×1 <0.0001 1.5 mA, ×3 versus 3.0 mA, ×3 <0.0001
BC versus 3.0 mA, ×2 <0.0001 3.0 mA, ×1 versus 3.0 mA, ×2 0.0002
BC versus 3.0 mA, ×3 <0.0001 3.0 mA, ×1 versus 3.0 mA, ×3 0.1438
1.5 mA, ×1 versus 1.5 mA, ×2 0.3646 3.0 mA, ×2 versus 3.0 mA, ×3 0.0286
Table 6 Statistical summary for fibroblasts cell serial injection experiment
Sample type Sample size (n) Mean (%)
Fibro, NTC 23 0.5383
Fibro, BC 24 5.7713
Fibro 1.5 mA, ×1 16 6.3556
Fibro 1.5 mA, ×2 15 4.9353
Fibro 1.5 mA, ×3 16 4.2588
Fibro 3.0 mA, ×1 16 15.1175
Fibro 3.0 mA, ×2 16 20.9738
Fibro 3.0 mA, ×3 14 17.4550
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glass coverslips. Future studies could also include treatment of the glass prior to seeding 
the cells to determine how various adhesive forces due to cell attachment may influence 
the efficiency of injection with various speeds.
Despite the decreases seen in the samples injected three times, the samples are still 
exhibiting relatively high levels of PI modification. For instance, the fact that the primary 
fibroblasts had a lower number of cells modified than the HeLa cells is not unexpected, 
particularly given the fact that BJ (ATCC® CRL-2522™) fibroblasts are difficult to mod-
ify (Avci-Adali et al. 2014). Even so, non-optimized delivery of PI still reached levels of 
20.97 %. Furthermore, it is clear that the magnitude of the current control used in Input 
1 has a dramatic impact on PI delivery and warrants further exploration.
Discussion: General
Since PI is able to diffuse from the cytoplasm to the nucleus, these data do not distin-
guish between cytoplasmic and nuclear injections, but simply identify the ability of 
the lance array to deliver PI into the cell. However, previous work using a single-lance 
nanoinjector for delivery of a transgene into fertilized mouse eggs demonstrated that the 
lance produces an intracellular electroporetic effect allowing cytoplasmic positioning of 
the lance to still yield nuclear delivery (Wilson et al. 2013).
The combination of results obtained for the speed of injection and the serial injection 
testing of the LAN represent three major findings. First, cell cultures are able to adhere to 
the glass slide used for staging the injection process much better when the speed of injec-
tion is reduced below 0.16 mm/s. Second, during serial injection testing, samples treated 
with 3.0 mA during Input 1 and injected twice appear to have the greatest mean percent 
of living, PI positive cells. Third, the cell type appears to have an effect on how well cells 
are modified by PI during the injection process, with HeLa cells performing better than 
primary, neonatal fibroblasts.
All three of these findings are viewed as particularly important milestones in regards 
to LAN because of how influential they are in establishing higher transfection rates. As 
noted earlier, there are several biotechnologies that have attempted to address the chal-
lenge of molecular delivery by non-viral means but are still plagued with transfection 
efficiency issues, which varying widely because of intrinsic weaknesses that are part of 
the technology or because of the cell type being transfected (Mellott et al. 2013).
Traditionally, viruses have been the benchmark for which transfection efficiency is meas-
ured. However, they fall short of meeting critical design requirements for robust transfection, 
particularly in preparation for clinical application. Adenoviruses, Adeno-associated viruses, 
and lentiviruses are all considered to have high transfection rates in a wide range of cell types 
(Gardlik et al. 2005; Silman and Fooks 2000). Unfortunately, adenoviruses are immunologi-
cally inflammatory which can be life-threatening (Bessis et al. 2004; Ritter et al. 2002), adeno-
associated viruses can cause insertional mutagenesis which can be cytotoxic (Deyle and 
Russell 2009; Monahan and Samulski 2000), and lentiviruses cause immunologic responses 
and insertional mutagenesis (Follenzi et al. 2007; Hacein-Bey-Abina et al. 2003, 2008; Mat-
rai et al. 2010; VandenDriessche et al. 2002). While retroviruses are useful in CNS (central 
nervous system) targets (Gardlik et al. 2005; Verma and Somia 1997), the risk of insertional 
mutagenesis is quite high (Gardlik et al. 2005). Furthermore, viruses in general are limited in 
their effectiveness because of the limited pay load capacity (≤10 kbp) (Gardlik et al. 2005).
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In contrast, LAN is able to by-pass many of these short-comings. First, LAN does 
not utilize protein vehicles which could cross-react with the immune system, thereby 
removing immunologic response issues. Second, LAN creates relatively large pores in 
target cells (1–2 μm diameter), allowing for large molecular loads to enter, thus reduc-
ing the concern of not having sufficient pay load capacity. Third, LAN is compatible with 
gene editing tools such as CRISPR-Cas9 that mitigate concerns regarding insertional 
mutagenesis. While the same can be said of viruses if re-programmed to remove self-
insertional mechanisms, LAN does not have the same preparatory work as viral deliv-
ery because insertional mutagenesis in the context of LAN is only an element directly 
related to the molecular load type, not LAN as a delivery method. To improve the suc-
cess rate of delivery using LAN, further work could include variations in initial current 
control settings, variations in pulsed voltage protocols, concentrations of the injection 
material, and types of molecules delivered.
Conclusion
Effectively placing molecular loads into target cells without threatening the cell’s survival 
is the overall goal of transfection biotechnologies. One non-viral method presented in 
this work is known as LAN, a MEMS based device that relies on physical interaction 
with target cells and electrical direction of molecular loads. Shown in two sequential 
experiments is the effect that the speed of injection and the ability to inject cells repeat-
edly have on target cells. In the speed of injection investigation, it was shown that slower 
injection speeds improve the number of cells still adherent following injection, reaching 
a peak mean of 99.3 % at 0.08 mm/s injection speed. Using these results, serial injection 
testing with HeLa 229 cells and BJ(ATCC® CRL-2522™) cells (neonatal, primary fibro-
blasts) were conducted by injecting samples multiple times (1, 2, and 3 times) at two 
different current control settings (1.5 and 3.0 mA). Results show that HeLa cells treated 
with 3.0 mA and injected twice (×2) had the greatest mean PI uptake of 60.47 % and 
that neonatal fibroblasts treated with the same protocol reached mean PI uptake rates 
of 20.97 %. Together these findings help to establish LAN as a method that can obtain 
modification rates comparable to other transfection technologies.
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